Skip to main content

Oligomeric vaccines

Ref-Nr: TA-ESA-I029


Kurzfassung

The invention provides a new approach for the generation of oligomeric vaccines. The underlying principle is the high affinity interaction between S-protein and S-tag. Oligomers are generated by co-expression of a modified S-protein and S-tag fusion proteins. High molecular vaccines have many advantages compared to recently used vaccines including high immunogenicity, high stability, short production time and lower production costs. The approach could therefore be used for the immunization of livestock.


Hintergrund

Immunization is an important tool to fight diseases caused by viral, bacterial or fungal pathogenes. There is an ongoing need to develop effective vaccines. Since many pathogens can easily spread from animal hosts to humans - the most prominent example being influenza - it has also to be considered to protect animals by vaccination. Most vaccines can however not be supplied in appropriate quantities in a short time and are too expensive for the application.


Bilder & Videos


Lösung

The invention provides a new approach for the generation of oligomeric vaccines. The underlying principle is the high affinity interaction between S-protein and S-tag of bovine pancreatic RNase A which is applied to hemagglutinin (H5). H5-Oligomers are generated by co-expression of H5-S-tag fusions and of a modified S-protein in a transient plant expression system. The obtained high molecular structures show a very high hemagglutination titer. The activity could clearly be related to these structures. It was shown that a specific immune response could be raised in mice after immunization. The oligomeric structures are stable in the plant extract for 1 week at 4° C with no loss of activity.


Anwendungsbereiche

The technology can be applied to produce high molecular vaccines. They have many advantages compared to recently used vaccines. The high molecular structures generated using the described novel approach:

  • are highly immunogenic
  • are highly stable
  • can be applied in the crude extract saving costs and time for downstream processing
  • can be produced in a short period of time
  • can be applied for broad immunization in veterinary medicine e.g. for poultry having an unlimited scalability.

We are seeking partners for developing specific vaccines based on the technology, or alternatively a licensee for the technology as a whole.


ESA Patentverwertungsagentur Sachsen-Anhalt GmbH

Dr. Sigrun Hähnel
+49 (0) 391 8107220
info@esa-pva.de
www.esa-pva.de
Adresse
Breitscheidstraße 51
39114 Magdeburg



Patentsituation

  • EP anhängig

Stichworte

Oligomer, multimer, S-Tag, modified S-Protein, interaction, influenza, hemagglutinin, H5N1, high affinity, stability, transient expression, plant, crude extract, specific immune response, immunization, poultry, veterinary, livestock, vaccination, vaccine

Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TechnologieAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsstellenleiterin)

c/o PROvendis GmbH
Schloßstr. 11-15
D-45468 Mülheim an der Ruhr